Precision-GI™ FDA Designated Breakthrough product and FDA cleared semi-automated motorized endoscopic biopsy device entering U.S. market YOKNEAM, Israel, Nov. 7, 2024 /PRNewswire/ -- The Centers for ...

CMS Transitional Pass-Through (TPT) Payment and completion of successful clinical studies position Limaca for US market entry. YOKNEAM, Israel, Feb. 18, 2025 /PRNewswire/ -- Limaca Medical Ltd.

YOKNEAM, Israel, Sept. 11, 2023 /PRNewswire/ -- Limaca Medical ("Limaca") announced today that its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device received 510(k) clearance from the U.S. Food ...

YOKNEAM, Israel, May 2, 2022 /PRNewswire/ -- Limaca Medical ("Limaca") announced today that its Precision-GI™ Endoscopic Ultrasound Biopsy Product has received a Breakthrough Device Designation from ...

GI cancers are estimated to account for almost 20% of new cancer cases in the United States in 2022. 1 The burden of GI malignancies continues to rise, with a projected increase in age-standardized ...

YOKNEAM, Israel, Nov. 7, 2024 /PRNewswire/ -- The Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for Limaca Medical Ltd. ("Limaca")'s Precision-GI™ ...

From an epidemiologic perspective, changing demographics have been observed with an increasing incidence in younger patients in certain GI malignancies, most notably in but not limited to colorectal ...